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Voltage-gated Na+ Channel 
Activity Increases Colon Cancer 
Transcriptional Activity and 
Invasion Via Persistent MAPK 
Signaling
Carrie D. House1,4, Bi-Dar Wang1, Kristin Ceniccola1, Russell Williams1, May Simaan2, 
Jacqueline Olender1, Vyomesh Patel2, Daniel T. Baptista-Hon3, Christina M. Annunziata4, 
J. Silvio Gutkind2, Tim G. Hales3 & Norman H. Lee1
Functional expression of voltage-gated Na+ channels (VGSCs) has been demonstrated in multiple 
cancer cell types where channel activity induces invasive activity. The signaling mechanisms by 
which VGSCs promote oncogenesis remain poorly understood. We explored the signal transduction 
process critical to VGSC-mediated invasion on the basis of reports linking channel activity to gene 
expression changes in excitable cells. Coincidentally, many genes transcriptionally regulated by the 
SCN5A isoform in colon cancer have an over-representation of cis-acting sites for transcription factors 
phosphorylated by ERK1/2 MAPK. We hypothesized that VGSC activity promotes MAPK activation to 
induce transcriptional changes in invasion-related genes. Using pharmacological inhibitors/activators 
and siRNA-mediated gene knockdowns, we correlated channel activity with Rap1-dependent 
persistent MAPK activation in the SW620 human colon cancer cell line. We further demonstrated that 
VGSC activity induces downstream changes in invasion-related gene expression via a PKA/ERK/c-
JUN/ELK-1/ETS-1 transcriptional pathway. This is the first study illustrating a molecular mechanism 
linking functional activity of VGSCs to transcriptional activation of invasion-related genes.
Membrane-spanning voltage-gated Na+ channels (VGSCs), important for neurite extension, neurotrans-
mitter release and cardiac excitation-contraction coupling, have been implicated in the metastatic poten-
tial of several different cancers. VGSCs are responsible for the depolarization phase of the action potential 
in excitable cells, such as neurons and cardiomyocytes, where their activation leads to an influx of Na+ 
into the cell1. Aberrant Na+ homeostasis can affect intracellular Ca2+ concentrations and pH, conditions 
that can alter intracellular signaling pathways. VGSC activity participates in the oncogenic potential of 
lung, prostate, breast, and colon cancers2–8. Importantly, these studies demonstrate that channel activity 
leads to increased invasion, whereas pharmacological blockade or genetic knockdown of specific VGSC 
isoforms inhibits invasion. The mechanism(s) by which these channels confer an oncogenic advantage 
remains unclear. Fluxes in pH can lead to extracellular acidification thereby enhancing the proteolytic 
activity of pH-dependent cathepsins for cellular invasion. It has been shown that the Na+/H+ exchanger 
type 1 partners with NaV1.5 to regulate H+ efflux and enhance invasiveness in breast cancer cells9,10. 
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A recent study showed that NaV1.5 allosterically regulates NHE-1 to promote invadopodia formation 
and activity in breast cancer cells11. A study investigating melanoma cell invasion demonstrated that 
activation of the NaV1.6 VGSC increased intracellular Ca2+ release and invadopodia formation12. It has 
also been proposed that membrane depolarization supports cancer stem cell populations by preventing 
maturation and/or differentiation13.
We have previously demonstrated that expression of the NaV1.5 isoform (encoded by SCN5A) is 
restricted to colon cancer tissues when compared to normal-matched controls and functional activity 
contributed to invasiveness of colon cancer cell lines4. Our work further showed that SCN5A participates 
in a colon cancer invasion-related gene network and regulates the expression of genes important for 
invasion. Lacking from these studies has been a comprehensive investigation of the signal transduction 
pathway(s) facilitating the oncogenic phenotype following VGSC activation.
The evolutionarily conserved mitogen activated protein kinase (MAPK) pathway, deregulated in 
many cancers, integrates extracellular signaling to cellular responses, such as replication, differentiation 
and apoptosis14. The MAPK signaling pathway is commonly activated in colon cancers and it has been 
suggested that all kinases (e.g. RAF, MEK and ERK isoforms) participating in this pathway could be 
potential targets for therapy15. In neurons, initiation of membrane depolarization by voltage-gated ion 
channels leads to activation of the ERK1 and ERK2 (ERK1/2) MAPKs, a process important for synaptic 
plasticity and neurogenesis16–18. The upstream signaling molecules responsible for ERK1/2 activation fol-
lowing membrane depolarization can include Ca2+ influx, calmodulin, cAMP-dependent protein kinase 
A (PKA), Ras and Rap1 (small GTPases of the Ras subfamily) and the Raf kinases16,17,19. Once activated, 
ERK1/2 translocates to the nucleus to phosphorylate and activate transcription factors (TFs), leading to 
changes in gene expression20.
Although evidence suggests that dysregulation of the MAPK pathway is important for colon cancer 
progression, no studies have examined the possible link between VGSC activity and aberrant stimulation 
of ERK1/2 in colon cancer cells. If such a link exists, it would also be informative to identify some of 
the effectors mediating VGSC stimulation of ERK1/2. As cancer cells are known to usurp and express 
various genes associated with excitable cells, which appear to facilitate invasion4,21, it is plausible that 
colon cancer cells may mimic many of the same signal transduction events found in neurons that lead 
to gene expression changes following ion channel activation. We show here that enhanced VGSC activ-
ity in colon cancer cells leads to increased ERK1/2 MAPK activity, whereas blockade of VGSCs had 
the opposite effect. We further demonstrate that VGSC-mediated stimulation of ERK1/2 was persistent 
and dependent on PKA, Rap1B (but not Rap1A) and MEK. Moreover, persistent ERK1/2 activation in 
colon cancer cells was associated with the following: i) enhanced TF binding to the proximal promoter 
region of genes associated with invasion, ii) transcriptional up-regulation of invasion-related genes, and 
iii) corresponding increase in invasive activity. Thus, we propose that NaV1.5 VGSC activity confers an 
oncogenic advantage to colon cancer cells by stimulating PKA/Rap1B/MEK/ERK1/2 to transcriptionally 
up-regulate genes required for invasion.
Results
Veratridine binds to activated VGSCs and prevents their inactivation leading to aberrant Na+ influx21. 
The effect of veratridine on VGSCs expressed in colon cancer cells is unknown. Therefore, we used 
the whole-cell recording technique to examine Na+ currents in voltage-clamped SW620 cells. We have 
previously demonstrated that depolarization activates VGSCs in SW620 cells with a maximum conduct-
ance activated at 20 mV4. Here we determined whether veratridine modulates Na+ currents recorded 
from SW620 cells. Consistent with our previous work, depolarization activates robust VGSC currents 
in SW620 cells (Fig. 1a). Application of veratridine (100 μ M) led to an enhancement of the steady-state 
current, as well as the appearance of a tail current upon repolarization (Fig.  1a). The net effect was a 
substantial increase in persistent Na+ current. We generated activation curves by plotting the conduct-
ance (normalized to maximum) at each voltage, in the absence or presence of veratridine (Fig.  1b). A 
Boltzmann function was fitted to the data to determine V½ values. Veratridine did not alter the V½ 
of activation in VGSCs expressed in SW620 cells. To examine the effects of veratridine on steady-state 
inactivation, SW620 cells were exposed to 100 ms pre-pulses to between − 140 mV and − 10 mV. The 
amount of available current was determined by stepping to 0 mV. Current values were converted into 
conductance and plotted as a percentage of maximum (Fig. 1b). The fit of the Boltzmann function to the 
steady-state inactivation data reveals that veratridine caused a small hyperpolarizing shift in the V½ of 
inactivation. This was accompanied by a reduction in the extent of inactivation increasing the amount of 
available current at more depolarized potentials ( > − 45 mV). The amount of current that was resistant 
to inactivation (as a percentage of peak current) was significantly increased in the presence of vera-
tridine (12 ± 2.2%; n = 10), when compared with controls (5.1 ± 1.9; n = 15; p < 0.05; unpaired t-test). 
The superimposed activation curves reveal the window current (Fig. 1b inset), which was increased by 
vetratridine.
We next determined whether veratridine could increase the invasive potential of colon cancer cells. In 
keeping with our previous study the ability of SW620 cells to invade Matrigel was significantly enhanced 
by veratridine22. Veratridine (100 μ M) enhanced invasion over a 24, 48 and 72 hr time period compared 
to vehicle control (Fig. 1c). Correspondingly, the veratridine-stimulated invasion was associated with a 
persistent activation of the MAPKs (beginning at 5 min and lasting up to 72 hr), as shown by western 
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Figure 1. Veratridine-enhanced Na+ current, invasion potential, and MAPK signaling. a) Representative 
voltage-activated Na+ currents recorded from voltage-clamped SW620 cells in the absence and presence 
of 100 μ M veratridine. Currents were activated by depolarizing to voltages between − 70 and +20 mV in 
10 mV steps. b) A graph depicting the voltage-dependence of activation and inactivation of conductance 
mediated by VGSCs in the absence (closed circles) or presence (open circles) of 100 μ M veratridine 
expressed as a percentage of maximal conductance. Data were fitted with a Boltzmann function, as described 
previously22. Values for V½ of activation and inactivation in the absence (− 4.9 ± 2.7 and − 86 ± 1.5 mV; 
n = 15, respectively) and presence of veratridine (− 2.4 ± 5.3 and − 95 ± 3.0 mV; n = 10, respectively) were 
determined as described in the Methods. The values for V½ of VGSC inactivation in the absence and 
presence of veratridine differed significantly (p < 0.05, unpaired t-test). The inset graph illustrates the 
predicted window of available current within the fits to activation and inactivation curves, in the absence 
(solid lines) and presence (dashed lines) of veratridine. Veratridine increases the size of the window current 
by reducing the extent of inactivation. c) Total number of invading SW620 cells as assessed by Matrigel assay 
over 24, 48 and 72 hr was significantly increased in the presence of 100 μ M veratridine. Vehicle is < 0.1% 
DMSO final concentration. d) Western blot analysis demonstrates increase in activated ERK that occurs 
with short exposure to veratridine. Note that slight diminution of total ERK1/2 at 5 min is loading artifact. 
e) Western blot analysis demonstrates increase in activated ERK that occurs with prolonged exposure 
to veratridine. Traces are representative of 3 independent experiments. Columns, mean from at least 3 
independent experiments; bars, SEM. * significantly different compared with vehicle control, P < 0.05, two-
sided unpaired t-test (c); * significantly different compared with vehicle control (0 min), P < 0.05, ANOVA 
with post-hoc Dunnett’s (d); * significantly different compared to 24, 48 and 72 hr vehicle control, P < 0.05, 
ANOVA with post-hoc Holm test, all other pairwise comparisons non-significant (e).
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blot analysis with an antibody specific to the phosphorylated (i.e. activated) form of ERK1/2 (Fig. 1d,e). 
This observation of MAPK pathway stimulation in response to VGSC activity in colon cancer cells is 
analogous to previous findings in neurons and more recently in endothelial cells16,23.
Having established that veratridine stimulates Na+ currents, invasion and persistent activation of 
ERK1/2 in colon cancer cells; we next investigated the effects of a VGSC blocker, lidocaine, on the 
aforementioned oncogenic parameters. We confirmed the ability of lidocaine to dose-dependently 
inhibit voltage-activated Na+ currents in SW620 cells. Na+ currents were activated by depolarizing from 
− 80 mV to 10 mV and lidocaine was applied to the recording chamber. The inhibitory effect of lidocaine 
on the peak Na+ current amplitude was established to produce a concentration-response relationship 
from which the IC50 was determined to be 19.9 + 2.5 μ M, with 100 μ M causing approximately 80% loss of 
current (Fig. 2a). The total number of invading SW620 cells was significantly reduced in the presence of 
100 μ M lidocaine compared with vehicle at 24, 48 and 72 hr (Fig. 2b). Lastly, 72 hr treatment of SW620 
cells with 100 μ M lidocaine led to a significantly lower level of activated ERK1/2 compared to vehicle 
control (Fig. 2c).
Figure 2. Inhibition of VGSC current reduces invasion potential and MAPK signaling. a) Lidocaine 
concentration-response relationship for inhibition of Na+ currents recorded from SW620 colon cancer 
cells. Currents were activated by stepping from a holding potential of − 80 mV to 10 mV. The inhibition was 
measured at the peak of the current. Data, fitted by using the logistic equation to determine the IC50 value 
for lidocaine, are presented as mean ± SEM of 5 independent experiments for each data point. The exemplar 
current reveals the inhibitory effect of 10 μ M lidocaine. The current is expanded to illustrate the inhibition 
of the peak current. b) Total number of invading SW620 cells over 24, 48 and 72 hr as assessed by Matrigel 
assay was significantly decreased in the presence of 100 μ M lidocaine, a local anesthetic that blocks VGSCs. 
Vehicle is <0.1% ethanol final concentration. c) Western blot analysis demonstrates the loss of activated ERK 
that occurs with 72 hr lidocaine (100 μ M) treatment. A representative western blot is shown (top). Results 
are means ± SEM from at least 5 independent experiments (a, b and c). * Significantly different compared 
with vehicle control, P < 0.05, two-sided unpaired t-test.
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As lidocaine has been shown to inhibit, in addition to VGSCs, other membrane-bound signaling 
molecules involved in oncogenesis24,25, the following experiments were employed to more conclusively 
demonstrate a link between VGSC activity and ERK1/2 phosphorylation and resultant invasive activity 
in SW620 colon cancer cells. Our previous work has demonstrated that NaV1.5 VGSC isoform (encoded 
by SCN5A) is responsible for invasivity of colon cancer cells as ‘knockdown’ of this isoform with either 
tetrodotoxin (TTX), a specific inhibitor of VGSCs, or siRNA-mediated targeting led to a significant loss 
of baseline invasion4. Treatment of SW620 cells with 30 μ M TTX alone resulted in a significant >2-fold 
decrease while, 100 μ M veratridine led to a significant increase in the total number of invading cells 
over a 48 hr time period (Fig. 3a). TTX reversed veratridine-stimulated invasion with the total number 
of invading cells returning to baseline levels of vehicle control-treated cells (Fig.  3a). Noteworthy was 
the finding that this reversal did not reach sub-baseline levels seen with TTX treatment alone (compare 
significant difference between TTX versus TTX + Veratridine in Fig.  3a). Next, the role of NaV1.5 in 
mediating 48 hr veratridine-stimulated phosphorylation of ERK1/2 in SW620 cells was assessed. Targeted 
Figure 3. Invasion potential and MAPK signaling is mediated by Nav1.5 isoform. a) Total number of 
invading cells is significantly decreased with 30 μ M TTX and significantly increased in the presence of 
100 μ M veratridine over a 48 hr time period. Veratridine-stimulated invasion is abrogated in the presence of 
TTX. b) siRNA-mediated knockdown of SCN5A significantly reduced activated ERK1/2 levels compared to 
cells treated with a nonsense siRNA and abrogated veratridine-stimulated ERK1/2 activation. Two separate 
siRNAs were combined (siSCN5A) for knockdown experiments (the 2 siRNAs were previously demonstrated 
to lack off-target effects)4. A nonsense siRNA (siNonsense) served as control. * Significantly different for all 
pairwise comparisons, # significantly different for all pairwise comparisons. P < 0.05, ANOVA with post-
hoc Holm test (a and b). Results are means ± SEM from at least 3–5 independent experiments for each data 
point.
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siRNA-mediated knockdown of SCN5A led to a significant decrease in ERK1/2 phosphorylation (com-
pare siNonsense control versus siSCN5A, Fig.  3b). In cells treated with a scrambled sequence siRNA 
(siNonsense), veratridine robustly stimulated ERK1/2 phosphorylation 2–3 fold. Analogous to our inva-
sion findings in Fig.  3a, knockdown of SCN5A reversed veratradine-stimulated ERK phosphorylation 
back to baseline but not sub-baseline levels (compare significant difference between siSCN5A versus 
siSCN5A + veratridine, Fig.  3b). This implies a minor veratridine-stimulated component that is inde-
pendent of SCN5A.
The findings taken as a whole (Figs 1–3) suggest that veratridine-stimulated ERK1/2 activity may lead 
to increased colon cancer cell invasion. To substantiate this hypothesis, ERK1/2 phosphorylation and 
invasion potential were assessed following inhibition of MEK, the upstream kinase responsible for phos-
phorylation and activation of ERK1/220. Under baseline conditions (no veratridine stimulation), SW620 
cells treated with the MEK inhibitor U0126 at 10 μ M or PD98059 at 25 μ M led to a significant decrease 
in invasion over a 48 hr period (Fig. 4a). We then examined whether inhibition of MEK could abrogate 
veratridine-stimulated invasion and ERK1/2 phosphorylation. In the presence of 10 μ M U0126, there 
was a reversal of veratridine stimulated invasion and a significant decrease in ERK1/2 phosphorylation 
following 48 hr veratridine stimulation (Fig. 4b,c). These data lend support to the idea that the MAPK 
pathway is persistently activated in response to VGSC activation in colon cancer cells.
Rap1, a small G protein important for neurite extension, adhesion and migration, is activated in 
response to depolarization16,26,27. Moreover, Rap1 activation can lead to persistent stimulation of the 
MAPK pathway28,29. To examine the role of Rap1 in the VGSC-mediated signaling in SW620 cells, a 
pull down assay was used to quantify the level of guanosine 5'-triphosphate (GTP)-bound Rap1 (active 
form) following 100 μ M veratridine treatment. Forskolin, a direct activator of adenylyl cyclase that leads 
to PKA stimulation and subsequent Rap1 activation, was used as a positive control. There was a sig-
nificant enhancement in active Rap1 levels as early as 5 min of treatment, and activated Rap1 persisted 
up to the longest treatment time point assayed, 24 hr (Fig.  5a). Next, SW620 cells were treated with 
individual siRNAs directed against Rap1A and Rap1B to determine isoform dependency in basal and 
48 hr veratridine-stimulated invasion of SW620 cells. When compared to unstimulated cells treated with 
a nonsense sequence siRNA (i.e. baseline invasion), unstimulated cells treated with siRNAs for knock-
down of either Rap1A or Rap1B displayed significantly less invasive phenotype over 48 hr (Fig.  5b). 
Furthermore, knockdown of either Rap1A or Rap1B led to a reversal of 48 hr veratridine-stimulated 
invasion back to baseline, but not sub-baseline, levels (Fig. 5c). In parallel with the loss of invasion, there 
was a significant loss in the levels of active ERK1/2 when 48 hr veratridine was given in the presence of 
Rap1B knockdown (Fig. 5d). In contrast, there was no change in active ERK1/2 levels when 48 hr vera-
tridine was given after knockdown of Rap1A (Fig. 5d).
Depolarization-induced stimulation of the MAPK pathway involving Rap1 in neuronal cells can be 
either PKA-dependent or -independent16,28. Therefore, the participation of PKA in veratridine-stimulated 
invasivity of colon cancer cells was investigated. We first measured the effects of the PKA inhibitor H89 on 
the baseline and veratridine-stimulated invasion of SW620 cells. In the presence of 10 μ M H89, baseline 
Matrigel invasion was significantly decreased over 48 hr (Fig. 6a). Likewise, H89 co-treatment impaired 
the ability of 100 μ M veratridine to increase SW620 cell invasion over 48 hr (Fig.  6b). Identical results 
were observed following targeted knockdown of the PKA catalytic subunit (PKAc) by two different siR-
NAs (Fig. 6c). Again it is noteworthy that knockdown of PKAc led to a reversal of veratridine-stimulated 
invasion back to baseline, but not sub-baseline, levels. In parallel experiments, 48 hr veratridine-induced 
phosphorylation of ERK1/2 was significantly impaired by the presence of 10 μ M H89 (Fig.  6d). Lastly, 
veratridine-stimulated GTP loading of Rap1 at 10 min and 24 hr was significantly inhibited following 
inhibition of PKA by 10 μ M H89 pretreatment (Fig.  6e). Taken together, these findings suggest that 
veratridine induces persistent ERK1/2 activation and associated SW620 cell invasion via a Rap1B- and 
PKA-dependent mechanism.
It has been shown that VGSC activation can stimulate adenylyl cyclase (AC) activity in a voltage-gated 
calcium channel (VGCC)-independent manner in neuronal cells30,31. We have previously demonstrated 
that VGSC activity stimulates invasion in colon cancer cells in a VGCC-independent manner4. Accordingly, 
we used a radioimmunoassay to test an involvement of elevated cAMP in the effects of 100 μ M veratri-
dine on SW620 cells across a range of time points. PKA-dependent invasion of SW620 cells may be due 
to elevated cAMP levels following veratridine-mediated activation of VGSCs. Cells were grown to con-
fluence and serum starved for 18 hr prior to drug treatment. Veratridine treatment did not significantly 
effect cAMP production compared to vehicle at any of the time points tested (Fig. 7a). Forskolin, a direct 
activator of adenylyl cyclase, was used as a positive control and significantly enhanced cAMP produc-
tion with 30 min exposure. Hence, these findings suggest that PKA-dependent invasion by SW620 cells 
does not involve accumulation and subsequent binding of cAMP to the PKA regulatory subunit (PKAr), 
which releases the PKAc subunit from inhibitory control. Besides PKAr, IkBα is a known inhibitor of 
PKA activity by forming an inhibitory complex with the PKAc subunit32. We therefore assessed the affect 
of veratridine stimulation on colocalization of PKAc with IkBα . Interestingly, veratridine treatment at 
15 min, 30 min and 24 hr, abrogated cytoplasmic colocalization of IkBα with PKAc (Fig. 7b). Moreover, 
western blot analysis demonstrated a significant degradation of IkBα following 30 min veratridine stim-
ulation (Fig.  7c). To determine whether forskolin-activated adenylyl cyclase could further enhance the 
veratridine-stimulated phosphorylation of ERK1/2, we analyzed phosphorylated ERK levels after 30 min 
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exposure to forskolin, veratridine and in combination and found no significant differences among these 
treatment groups (Supplemental Fig. S1). These findings confirm a cAMP-independent mechanism for 
veratridine-stimulated ERK1/2 activation.
The combination of persistent activation of the PKA/Rap1B/MEK/ERK pathway resulting from 
veratridine-induced stimulation of VGSC activity and subsequent increase in invasive potential of SW620 
cells (24–72 hr) is highly suggestive of a downstream transcriptional mechanism. A number of TFs are 
known to be activated by ERK1/233 . Consequently, we evaluated the involvement of the promoter regions 
of genes previously shown to be transcriptionally regulated following SCN5A knockdown4. PROMO 
was used to evaluate DNA sequences for TF binding sites (http://alggen.lsi.upc.es/cgi-bin/promo_v3/
promo/promoinit.cgi?dirDB = TF_8.3). The first 5000 bases upstream of the transcription start site were 
screened for TF binding motifs that correspond to transcription factors regulated by ERK1/233. Several 
Figure 4. MAPK signaling contributes to invasion potential of colon cancer cells. a) Inhibition of MEK 
by either 10 μ M U0126 or 25 μ M PD98059 significantly reduces invasion over 48 hr. U0126 treatment 
abrogates both (b) veratridine-stimulated invasion and (c) MAPK activity over a 48 hr time period in 
SW620 cells. Results are means ± SEM from at least 4 independent experiments for each data point. * 
Significantly different from Vehicle Control, P < 0.05, ANOVA with post-hoc Dunnett’s (a); * significantly 
different for all pairwise comparisons, P < 0.05, ANOVA with post-hoc Holm test (b); * significantly 
different from Veratridine, P < 0.05, two-sided unpaired t-test (c).
www.nature.com/scientificreports/
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Figure 5. Veratridine signals through Rap1 to enhance invasiveness and persistent MAPK signaling in 
colon cancer cells. a) SW620 cells were serum starved for 24 hr prior to treatment with 100 μ M veratridine 
for time periods indicated. A 10 min, 10 μ M forskolin treatment was included as a positive control. Cell 
lysates were subjected to pulldown assay for detecting activated GTP-bound Rap1. An increase in GTP-
bound Rap1 can be seen starting at 5 min and persists through 24 hr. b) siRNA-mediated knockdown 
of Rap1A and Rap1B inhibited basal SW620 invasion through Matrigel at 48 hr. Two separate siRNAs 
(− 1 and − 2) were employed for each Rap1 isotype. A nonsense siRNA (siNonsense) served as control. 
c) siRNA-mediated knockdown of Rap1A and Rap1B inhibited veratridine-stimulated SW620 invasion 
through Matrigel at 48 hr. d) siRNA-mediated knockdown of Rap1B (siRAP1B), but not Rap1A (siRAP1A), 
inhibited veratridine-stimulated ERK1/2 activity at 48 hr. Representative western blot provided above bar 
graph. In the experiments depicted in panels c and d, both siRNAs (− 1 and − 2) for each respective Rap1 
isotype were combined for knockdown experiments, as off-target effects were not observed (see panel 
b). The combination of siRNAs led to greater knockdown efficiency as defined by qRT-PCR of Rap1B 
and Rap1B mRNAs. Results are means ± SEM from at least 4 independent experiments for each data 
point. * Significantly different from siNonsense control, P < 0.05, ANOVA with post-hoc Dunnett’s (b); 
* significantly different for all pairwise comparisons, # significantly different for all pairwise comparisons 
(except for siRAP1A versus siRAP1B), P < 0.05, ANOVA with post-hoc Holm test, all other pairwise 
comparisons non-significant (c and d).
www.nature.com/scientificreports/
9Scientific RepoRts | 5:11541 | DOi: 10.1038/srep11541
Figure 6. Veratridine signals through PKA to enhance invasiveness and persistent MAPK signaling 
in SW620 colon cancer cells. a) Baseline Matrigel invasion by SW620 cells over 48 hr was significantly 
decreased in the presence of 10 μ M H89, a PKA inhibitor. b) Veratridine-stimulated (100 μ M) invasion by 
SW620 cells at 48 hr was inhibited by pretreatment with 10 μ M H89. c) Veratridine-stimulated (100 μ M) 
invasion by SW620 cells at 48 hr is inhibited by siRNA-mediated knockdown of PKA. Two separate siRNAs 
targeting both the alpha and beta PKA catalytic subunit isoforms were employed in knockdown experiments 
(siPKAc-1 = siPKACA_1 + siPKACB_1, and siPKAc-2 = siPKACA_2 + siPKACB_2). d) Western blot 
analysis demonstrated an inhibition of 100 μ M veratridine-stimulated ERK1/2 phosphorylation in SW620 
cells at 48 hr following 10 μ M pretreatment with the PKA inhibitor H89. Representative blot is shown (top). 
e) Veratridine-stimulated Rap1 loading of GTP is inhibited by 10 μ M pretreatment with the PKA inhibitor 
H89. Forskolin (10 μ M) served as a positive control. Representative blot is shown (top). Results are means 
± SEM from at least 3–6 independent experiments for each time point in a-e. * Significantly different from 
vehicle control, P < 0.05, two-sided unpaired t-test (a); * significantly different for all pairwise comparisons 
(b-d), # significantly different for all pairwise comparisons except for siPKAc-1 versus siPKAc-2 (b and 
c), P < 0.05, ANOVA with post-hoc Holm test, all other pairwise comparisons non-significant (b-d); * 
significantly different from Vehicle Control, P < 0.05, ANOVA with post-hoc Dunnett’s (e).
www.nature.com/scientificreports/
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Figure 7. Veratridine does not promote cAMP accumulation but abrogates co-localization of IkBα 
and PKA. a) SW620 cells were grown to confluence in 12 well plates and serum starved for 18 hr prior 
to treatment with 100 μ M veratridine or 10 μ M forskolin for the indicated time periods. Veratridine 
stimulation did not induce accumulation of cAMP (as measured by RIA) compared to control (0 min). 
Forskolin treatment (positive control) induced a significant increase in cAMP immunoreactivity. Results 
are means ± SEM from at least 3 independent experiments for each time point. b) Veratridine stimulation 
(100 μ M) reverses cytoplasmic colocalization of PKA and IKBα . Confocal immunofluorescence of SW620 
cells were triple-stained for PKA catalytic subunit alpha isoform 2 (green), IkBα (red) and nuclei by 
DAPI (blue). PKA/IkBα colocalization shown in yellow (PKA/IkBα colocalize panels). Confocal images 
are representative of 6 independent experiments. c) Western blot analysis demonstrates veratridine-
stimulated ERK1/2 phosphorylation in SW620 cells at 30 min correlates with IkBα degradation. Results are 
means ± SEM from at least 3 independent experiments, * Significantly different from 0 min control, P < 0.05, 
ANOVA with post-hoc Dunnett’s (a); * significantly different from Vehicle P < 0.05, two-sided unpaired 
t-test (c).
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SCN5A-regulated genes, including CD44, CLIC4, ITGB1, SEMA6A, VEGFC, WNT9A and HIF1A were 
shown to have motifs within 1000 bases of the transcription start site for TFs regulated by ERK1/2, 
namely c-JUN, ETS-1, and ELK-1. Treatment of SW620 cells with 100 μ M veratridine for 24 hr resulted 
in a significant 2–12 fold increase in CD44, CLIC4, ITGB1, SEMA6A, VEGFC, WNT9A mRNAs, and a 
5-fold decrease in HIF1A mRNA (Fig. 8a). The veratridine-stimulated changes in gene expression were 
dependent on both PKA and ERK1/2, as treatment of SW620 cells with either 10 μ M H89 or 10 μ M 
U0126, respectively, abrogated these transcriptional changes (Fig. 8a). We tested a subset of these genes 
and confirmed that veratridine treatment significantly increased ERK1/2-regulated TF binding to CD44, 
CLIC4, ITGB1, VEGFC and WNT9A gene promoters based on ChIP-PCR (Fig.  8b). Finally, we tested 
siRNA-mediated knockdown of WNT9A, ITGB1 and CD44 in SW620 cells and demonstrate a reversal of 
veratridine-stimulated Matrigel invasion (Fig. 8c). Our results define a PKA/Rap1B/MEK/ERK/c-JUN/
ELK-1/ETS-1 transcriptional pathway that is activated by VGSCs leading to increased invasive potential.
Discussion
Increasing evidence suggests that ion channels are key contributors to the oncogenic behavior of cancer 
cells13. We have previously demonstrated that the NaV1.5 VGSC contributes to the invasion potential of 
colon cancer cells and regulates an invasion-related gene network for colon cancer4. The current study 
sought to elucidate the signaling pathway by which these channels regulate gene expression changes 
important for oncogenic potential.
It has been proposed that VGSC activity increases invasiveness of cancer cells by facilitating activation 
of specific proteases or by inducing podosome formation9,12. Although these mechanisms might apply to 
colon cancer as well, we chose to evaluate transcriptional changes that might occur as a result of NaV1.5 
expression and activation. There have been no systematic studies examining VGSC activity together 
with changes in gene expression and invasion potential of cancer cells. Ion channel activity stimulates 
a variety of intracellular signaling pathways and the functional state of ion channels is known to affect 
gene expression in neuronal and skeletal muscle cells34–36.
In an effort to understand cancer signaling mechanism(s) connecting VGSC activity to transcriptional 
changes in invasion-related genes, we tested a model based on the known signaling consequences of 
VGSC activation in excitable cells in which voltage-gated ion channels are normally expressed. Given 
that many neuronal genes are usurped during colon cancer progression, it is possible that pathways acti-
vated by depolarization in excitable cells may also be activated in cancer cells. The MAPK pathway is a 
well-established signal transduction pathway deregulated in about 1/3 of all cancers and coincidentally 
is activated in response to depolarization of neurons14,16. Upon activation, the ERK1/2 MAPKs can acti-
vate various TFs including ELK1, ETS-1, and c-JUN, among others14,37. The promoter regions of genes 
directly regulated by NaV1.5 knockdown in colon cancer cell lines were analyzed in the present study 
and determined to have overrepresented binding motifs corresponding to ERK-regulated TFs. This study 
confirmed that pharmacological manipulation of VGSC activity led to changes in both ERK1/2 activity 
and chromatin binding of ERK-regulated TFs to SCN5A-dependent genes. These observations led us to 
postulate that NaV1.5 VGSCs signal through the ERK MAPK pathway to transcriptionally regulate genes 
that drive colon cancer invasion.
Despite expression of VGSCs and other genes associated with excitable cells, SW620 colon cancer cells 
appear not to be electrically excitable. They have a depolarized membrane potential of approximately 
− 40 mV22. A comparison of the voltage-dependence of current activation with that of steady-state inac-
tivation reveals that there is a window of available current remaining at − 40 mV4. While NaV1.5 chan-
nels are predominantly in the inactivated state at this potential they briefly visit the active conformation 
allowing some persistent Na+ entry. Blockade of NaV1.5 VGSCs by lidocaine at concentrations within 
the micromolar range occurs through high affinity use-dependent binding that requires depolarization38 . 
Through this mechanism lidocaine preferentially blocks channels in the open and inactivated states and 
provides an opportunity for selective inhibition of Na+ entry into VGSCs of colon cancer cells with-
out affecting Na+ entry into cardiac cells. Conversely, veratridine enhances steady-state current through 
NaV1.5 VGSCs of SW620 cells resulting in reduced inactivation. This results in a large increase in the 
availability of steady-state current through VGSCs at depolarized membrane potentials. Similar findings 
have previously been reported for the effects of veratridine on NaV1.6 VGSCs39.
Pharmacological and genetic tools were used to probe changes in invasiveness and ERK1/2 activity in 
colon cancer cells to identify additional participating signaling molecules. Although activation of VGCCs 
is known to occur following depolarization of neurons to stimulate MAPK16, our previous work sug-
gested a VGCC-independent mechanism4. Furthermore, it has been demonstrated that Na+ can directly 
activate AC to stimulate cAMP production30. However, we observed that VGSC activation did not lead 
to any appreciable cAMP accumulation in SW620 colon cancer cells. These findings suggest a VGSC 
signaling mechanism leading to MAPK activation that is, in this respect, distinct from that observed in 
excitable cells.
Our study demonstrates that persistent activation of ERK1/2 MAPKs following veratridine stimu-
lation is PKA-dependent in colon cancer cells. This is an intriguing finding, given that PKA activity 
is important for depolarization-induced signaling to the MAPKs in neurons16,29,40. In addition, our 
study suggests that VGSCs signal through PKA in a cAMP-independent manner to enhance ERK1/2 
activity and invasion of colon cancer cells. A number of studies have demonstrated cAMP-independent 
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Figure 8. Activation of sodium channels induces expression changes of invasion-related genes via a 
PKA/ERK/c-JUN/ELK-1/ETS-1 transcriptional pathway. a) Veratridine-stimulation of invasion-related 
gene expression in SW620 cells at 24 hr was reversed by pretreatment with the PKA inhibitor H89 and MEK 
inhibitor U0126. qRT-PCR results of invasion-related gene expression in SW620 cells treated with vehicle, 
100 μ M veratridine, 100 μ M veratridine +10 μ M H89, or 100 μ M veratridine +10 μ M U0126. b) Veratridine 
increased binding of transcription factors ETS1, c-Jun and ELK1 to invasion-related genes as shown 
by ChIP-PCR. Representative blots are depicted above bar graphs. ACTB (actin B) served as a negative 
control where veratridine stimulation did not increase transcription factor binding to the ACTB promoter 
compared to vehicle-treated cells. IP, immunoprecipitation of transcription factor bound to chromatin; No 
Ab, no antibody treatment control. c) siRNA-mediated knockdown of invasion-related genes abrogated 
veratridine-stimulated invasion of SW620 cells through Matrigel at 48 hr. Results are means ± SEM from at 
least 3–6 independent experiments for each time point in a-c. * Significantly different from corresponding 
vehicle control, P < 0.05, ANOVA with post-hoc Dunnett’s (a); * significantly different from corresponding 
vehicle control, P < 0.05, two-sided unpaired t-test (b); * significantly different for all pairwise comparisons, 
P < 0.05, ANOVA with post-hoc Holm test (c).
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activation of PKA41–44. For example, a cytosolic pool of PKAc can associate with NF-kB p65 and I kBα 
as part of an inhibitory complex32. Following signaling events leading to phosphorylation of I kBα , the 
inhibitory complex dissociates, leading to proteasomal degradation of I kBα and the freeing of PKAc. 
This appears to be the likely mechanism in SW620 cells as veratridine stimulation abrogates colocali-
zation of PKAc and I kBα and induces IkBα degradation with a time course that induces both Rap1B 
and ERK1/2 activation. Alternative cAMP-independent mechanisms for induction of PKA activity may 
include stimulation by sphinogsine, a signaling intermediate of the sphingomyelin pathway41,42. Future 
studies will clarify VGSC-activated signaling events leading to phosphorylation of NF-kB p65 and PKAc 
release, and whether additional cAMP-independent mechanisms may be involved in PKA activation in 
colon cancer cells.
In addition to PKA the involvement of the small G protein Rap1 in depolarization-induced signaling 
to MAPK has been well-characterized16,28,29,40. Activation of Rap1A promotes invasive and metastatic 
potential of prostate cancer cell lines23, including those cell lines shown to express VGSCs43. However, a 
link between VGSC activity and Rap1 stimulation in mediating prostate cancer cell invasion/metastasis 
has not been established. Thus, we investigated the participation of Rap1 in the VGSC signaling in colon 
cancer cells and found that VGSCs signal through both Rap1A and Rap1B to increase invasion poten-
tial. Rap1 activation occurred within 5 min of veratridine treatment and persisted for at least 24 hr in a 
PKA-dependent manner. The data further suggest that although VGSCs signal through both Rap1A and 
Rap1B in colon cancer cells, Rap1B activation in particular leads to persistent ERK1/2 MAPK activation. 
It is possible that upon activation, Rap1A signals through an integrin-dependent mechanism, which 
has been shown for prostate cancer cells26, while Rap1B signals to MAPK to enhance colon cancer cell 
invasion. This possibility is further supported by the fact that Rap1B is phosphorylated and activated 
by PKA44, and VGSC signaling to ERK1/2 requires PKA and Rap1B in colon cancer cells (this study).
Taken together, our inhibitor and knockdown experiments suggest that veratridine-stimulated invasion 
by SW620 colon cancer cells is mediated by an SCN5A-dependent pathway involving PKA/RAP1B/MEK/
ERK (predominant pathway). As inhibitor and knockdown treatments reversed veratridine-stimulated 
invasion to baseline but not sub-baseline levels (i.e. inhibitor or knockdowns in the absence of vera-
tridine), a second minor SCN5A-independent pathway may also be present. The nature of this minor 
component remains to be elucidated, but may involve K+ and/or Ca++ channels that are known to 
be stimulated by veratridine in a TTX-independent fashion45,46. Finally, this study along with our pre-
vious findings strongly support the notion that NaV1.5 is the primary VGSC subunit responsible for 
veratridine-stimulated ERK1/2 phosphorylation and corresponding invasive activity in SW620 colon 
cancer cells. First, knockdown of SCN5A inhibits veratridine-stimulated phosphorylation of ERK1/2 
back to baseline levels; and second, SCN5A mRNA is the major VGSC mRNA species expressed in 
SW620 cells4.
In conclusion, we provide evidence for VGSCs in colon cancer cells signaling through a novel pathway 
that is VGCC-independent, cAMP-independent and involves PKA, Rap1B, MEK and persistent activa-
tion ERK1/2, leading ultimately to transcriptional induction of invasion-related genes. These important 
data highlight the contribution of VGSCs to the metastatic potential of colon cancer cells and suggest 
that pharmacological manipulation of channel activity may provide clinical benefit. Given the broad 
toxicity of current therapies, a more targeted approach blocking VGSC activity may provide a better 
tolerated alternative treatment.
Recent mouse xenograft studies with human breast cancer cells demonstrate that the VGSC inhibitors, 
phenytoin, an antiepileptic drug, and the antiarrhythmic agent ranolazine, inhibit invasion and metas-
tasis in vivo47,48 . It may be beneficial to repurpose such drugs for use in the treatment of breast cancer. 
Our study further suggests that administration of local anesthetics during surgical resection should be 
explored as a potential therapeutic strategy for the prevention of metastases. There is an urgent need for 
the development of drugs that inhibit metastasis given that the majority of the classic cytotoxic chem-
otherapeutic drugs in current use only target cell proliferation. In light of our work in colon cancer, 
studies identifying a role for VGSCs in the progression of other human cancers and the typically large 
therapeutic window characteristic of many VGSC modulators, it is worthwhile to further explore the 
feasibility of VGSC modulators in cancer therapy.
Methods
Cell Culture- SW620 human colon cancer cells (Catalog No. CCL-227) were obtained directly from 
American Type Culture Collection (ATCC). Cells were maintained in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% heat inactivated fetal bovine serum (FBS), 2 mM L-glutamine and 
penicillin-streptomycin (Gibco, Grand Island, NY) at 37 °C and 5% CO2. All experiments were per-
formed using cells passaged less than ten times.
RNA Extraction and Quantitative RT-PCR- Total RNA was isolated from cells using Trizol (Invitrogen, 
Carlsbad, CA) extraction according to manufacturer’s instructions. Crude RNA was purified using RNeasy 
Mini Kit (Qiagen, Valencia, CA) as described by the manufacturer and treated with DNase to remove con-
taminating DNA. The final concentration of RNA was determined using a NanoDrop spectrophotometer 
(NanoDrop Technologies, Inc., Wilmington, DC). RNA integrity was confirmed using the 260/280 absorb-
ance ratio and agarose gel electrophoresis. RNA was stored at − 80 °C. Total purified RNA was reverse tran-
scribed with random primers using Taqman reverse transcription reagents (Applied Biosystems, Carlsbad, 
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CA). Resulting cDNA was used as a template for qRT-PCR. PCR primers were designed using Primer3 
and selected for specificity using the NCBI BLAST tool. Analysis of gene expression was performed 
on an ABI Prism 7300 Sequence Detection System using SYBR green (Applied Biosystems, Carlsbad, 
CA). Amplicon specificity was verified by first-derivative melting curve analysis. Housekeeping genes, 
pyrophosphatase (inorganic) 1 (PPA1) and eukaryotic translation initiation factor 1 A, X-linked (EIFAX) 
(Genbank Accession number NM_021129 and NM_001412, respectively), were used for normalization. 
Quantitation and normalization of relative gene expression were accomplished using the comparative 
threshold cycle method or Δ Δ CT. Primer sequences are provided in Supplemental Table 1.
Electrophysiology- Cells were cultured for 48 hr to 30% confluence in 35-mm dishes for electrophys-
iological studies. The whole-cell patch-clamp technique was used to record voltage-activated currents 
from individual cells. The electrode solution contained 130 mM CsCl, 15 mM NaCl, 2 mM MgCl2, 
10 mM EGTA, and 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (pH 7.4). The 
extracellular solution used for recording Na+ currents contained 140 mM NaCl, 4.7 mM KCl, 1.2 mM 
MgCl2, 2.5 mM CaCl2, 10 mM HEPES, and 11 mM glucose (pH 7.4) with and without the indicated 
concentrations of lidocaine. Veratridine was diluted in extracellular solution and bath applied. Currents 
were recorded using an Axopatch 200 B amplifier, low-pass filtered at 5 KHz, digitized at 10 KHz using a 
Digidata 1320 A interface, acquired using pCLAMP8 software, and analyzed using Clampfit 10.1 software 
(all from Molecular Devices, Sunnyvale, CA). Current-voltage relationships were recorded with depolar-
izing steps from − 80 mV to +70 mV in 10 mV steps. Steady state inactivation data were recorded from 
cells exposed to 100 ms pre-pulses to voltages between -140 mV and − 10 mV before activation to 0 mV. 
Activation and inactivation curves were derived and fitted with a Boltzmann function as described pre-
viously22. The logistic equation was used to fit data and determine IC50 values for lidocaine.
siRNA Transfections- Cells were cultured for 24 hr to 50% confluence before transfection with 
Dharmacon On-Targetplus short interfering RNA (siRNA) duplexes according to manufacturer’s instruc-
tions (Thermo Fisher Scientific, Lafayette, CO). Briefly, cells were transfected with Dharmafect 4 trans-
fection reagent and individual siRNAs at a final concentration of 1% v/v and 100 nM, respectively. Cells 
were maintained in the presence of transfection reagent under normal culture conditions for 24–48 hr 
before being used in qRT-PCR, western blot analysis, and Matrigel experiments. Two different siRNAs 
were employed for each gene knockdown and knockdown efficiency, ranging from 60–90% compared to 
nonsense siRNA control, was confirmed for all assays (i.e. gene expression, western blot and Matrigel) by 
qRT-PCR (Supplemental Fig. S2). siRNA sequences are provided in Supplemental Table 1.
Western Blots- Cells were grown to 80% confluence and lysates collected using RIPA lysis buffer 
(Santa Cruz Biotechnology, Santa Cruz, CA). Protein concentration was determined using NanoOrange 
Protein Quantitation Kit (Molecular Probes, Invitrogen, Eugene, OR). Fifty μ g of protein was separated 
using standard SDS-PAGE with precast 4–20% gels (BioRad, Hercules, CA) and transferred to PVDF 
membranes using standard transfer conditions. Transfer conditions for Rap1 blots was overnight at 20 V 
and all other protein blots were 1 hour at 100 V. Membranes were washed with TBST and blocked for 
at least one hour using 5% BSA or 5% powdered milk (Rap1 westerns). The NaV1.5 antibody is goat 
polyclonal purchased from Santa Cruz Biotechnology. All remaining antibodies used in this study are 
rabbit polyclonal, purchased from the following distributors: phospho-ERK1/2 (Cell Signaling, Danvers, 
MA), IKBα , Erk1 and Rap1 (Santa Cruz, Technologies, Santa Cruz, CA), GAPDH (mouse) (Millipore, 
Temecula, CA). Membranes were incubated with primary antibodies diluted in 5% BSA for at least 2 hr at 
4 °C. Membranes were washed 3–4 times using TBST. Membranes were incubated with HRP-conjugated 
secondary antibody (Santa Cruz Biotechnology) diluted in 5% milk for 1 hour at room temperature. 
After four washes, membranes were incubated with enhanced chemiluminescence substrate (Perkin 
Elmer, Waltham, MA) for 5 min and exposed to autoradiography film for 1 min. Films were scanned 
using a Personal Densitometer SI (Molecular Dynamics, Sunnyvale, CA) and protein bands quantified 
using ImageQuant software. Membranes were incubated in stripping buffer (2% SDS, 62.5 mM Tris-HCl, 
100 mM β -mercaptoethanol) for 15 min at 50 °C to allow stripping of initial antibodies. Membranes were 
then incubated with control antibodies for quantification and normalization.
Matrigel Invasion Assays- Cells (3 × 105 or 6 × 105 for stimulatory or inhibitory studies, respectively) 
were seeded in the top well of a Matrigel-coated invasion chamber (BD Biosciences) in DMEM contain-
ing 0.1% serum with or without pharmacological agents. The bottom well was filled with 750 μ L DMEM 
containing 10% serum as a chemoattractant with or without pharmacological agents. After 24–72 hr, 
non-invading cells were scraped from the upper side of the insert using a cotton swab. Invading cells 
on the bottom of the insert were fixed and stained with Diff-Quick Stain (IMEB, Inc., San Marcos, CA) 
according to manufacturer’s instructions. The total number of invading cells was counted for each insert 
under a light microscope.
cAMP Radioimmunoassay- Cells were grown to confluence in 12-well plates and serum-starved for 
18 hr. Cells were pretreated with 1 mM 3-isobutyl-1-methylxanthine (IBMX) for 20 min to inhibit cAMP 
phosphodiesterases, followed by agonist treatment for the indicated times at 37 °C. Cold ethanol was 
used to extract cAMP from the cells. The resulting pellet was resuspended in 200 μ l assay buffer and 
cAMP levels were detected in duplicate using a 125I radioimmunoassay kit according to manufacturer’s 
instructions including the acetylation procedure (Perkin Elmer, Waltham, MA). Samples were counted 
using a one minute counting time in a Packard Cobra II gamma counter. A standard curve was generated 
in Microsoft Excel and counts were converted to pmol per well.
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Rap1-GTP Pull-Down Assays- The cDNA of the effector of Rap1 (Rap1 binding domain of RalGDS) 
cloned into BL21 Escherichia coli cells was a generous gift from Atsuko Sakurai. Bead slurries were pre-
pared as previously described49 and stored at 4 °C until ready to use. SW620 cells were grown in 10 cm 
plates to 70% confluence and serum starved for 18 hr before treating with drugs at indicated time points. 
The cells were washed with cold PBS and lysed using lysis buffer with protease inhibitors (20 mM HEPES 
(pH 7.5), 1% Triton X–100, 100 mM NaCl, 20 mM MgCl2, EGTA, β -glycerol phosphate, 1 mM PMSF, 
10 μ g/ml aprotinin and leupeptin, 1 mM Na3VO4, 1 mM Dithiothreitol (DTT), and water). Lysates were 
centrifuged at 13,200 rpm at 4 °C for 10 min. For total cell lysates, 50 μ l precleared lysates were immedi-
ately placed in 50 μ l 2X Laemmli sample buffer and stored at 4 °C. For pull down lysates, 450 μ l precleared 
lysates were incubated with 20 μ l GST-RalGDS bead slurry at 4 °C with rotation for 30 min. Pull down 
lysates were then centrifuged, washed with lysis buffer, and resuspended in 50 μ l 2X Laemmli sample 
buffer and stored at 4 °C. Pull down and total cell lysates were then subjected to standard SDS-PAGE.
Chromatin Immunoprecipitation-PCR (ChIP-PCR) Assays- ChIP Assay Kit was purchased from 
Millipore Corp., and assays were performed according to the manufacturer’s instructions and as pre-
viously described50. Antibodies for EST1 (ab10936), c-JUN (ab31419), and ELK1 (ab28831) were from 
Abcam (Cambridge, MA). The quantification of transcription factor binding to target genes was calcu-
lated by measuring the ratio of ChIP-to-Input, and the non-antibody treated ChIP sample served as a 
negative control. All primers used for ChIP-PCRs are listed in Supplemental Table 1.
Immunocytochemistry (ICC)- ICC in SW620 cells was performed as previously described51. Antibodies 
for PKA (catalytic subunit alpha isoform 2, ab26322)) and IKBα (sc-1643) were purchased from Abcam 
(Cambridge, MA) and Santa Cruz Biotechnology (Santa Cruz, CA), respectively.
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